BACKGROUND AND PURPOSE The Albumin in Acute Stroke (ALIAS) Part 2 Trial is directly testing whether 2 g/kg of 25% human albumin (ALB) administered intravenously within 5 hours of ischemic stroke onset results in improved clinical outcome. Recruitment into Part 1 of the ALIAS Trial was halted for safety reasons. ALIAS Part 2 is a new, reformulated trial with more-stringent exclusion criteria. Ou...

This paper describes the design and implementation of the Lucent Personalized Web Assis tant LPWA LPWA is a software system that enables a user to browse the Web in a person alized simple private and secure fashion and to lter junk e mail spam LPWA generates secure consistent and pseudonymous aliases personae for Web users Each alias consists of an alias username an alias password and an alias ...

T paper introduces and studies an optimization problem related to the alias method for discrete randomvariate generation. The alias method is an efficient method to generate random variates from a discrete probability distribution. The efficiency of the alias method can be improved by designing the alias table such that the expected number of computations that must be performed per value genera...

In theory, increasing alias analysis precision should improve compiler optimizations on C programs. This paper compares alias analysis algorithms on scalar optimizations, including an analysis that assumes no aliases, to establish a very loose upper bound on optimization opportunities. We then measure optimization opportunities on thirty-six C programs. In practice, the optimizations are rarely...

To function on programs written in languages such as C that make extensive use of pointers, automated software engineering tools require safe alias information. Existing alias-analysis techniques that are suuciently eecient for analysis on large software systems may provide alias information that is too imprecise for tools that use it: the impreci-sion of the alias information may (1) reduce th...

See related article, pages 1621–1625 As noted by Hill et al,1 the need for neuroprotective agents has never been greater. However, few would describe the trek to discover an efficacious neuroprotective agent as anything other than a frustrating and expensive journey. But as suggested in a quote attributed to Charles Noble, “You must have long-range goals to keep you from being frustrated by sho...